2019冠状病毒病大流行与接受疾病修正治疗的多发性硬化症患者的感染风险：“我们到底知道些什么？”
COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: "what the bleep do we know?".
作者信息
Mansoor Salman, Kelly Siobhan, Murphy Kevin, Waters Aine, Siddiqui Nauman Saleem
机构信息
1Department of Neurology, Sligo University Hospital, Sligo, Ireland.
Division of Adult Haematology, Tufts Medical Centre, Boston, USA.
出版信息
Egypt J Neurol Psychiatr Neurosurg. 2020;56(1):44. doi: 10.1186/s41983-020-00177-0. Epub 2020 May 1.
Abstract
The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a "Pandemic" and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strategies which are being deployed. Multiple sclerosis patients who are on disease modifying therapies (DMTs) might be at a higher risk of acquiring or a poorer outcome due to their immune status. This review looks at the available evidence in managing this global crisis.
摘要
在中国湖北省出现的新型冠状病毒令世界震惊。自2019年12月被确诊以来，它已被称为“大流行”，全球医生对此的担忧也与日俱增。随着新证据的出现，人们正在部署各种预防策略。正在接受疾病修正疗法（DMTs）的多发性硬化症患者，由于其免疫状态，可能有更高的感染风险或更差的预后。本综述着眼于应对这一全球危机的现有证据。
相似文献
1
COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: "what the bleep do we know?".
Egypt J Neurol Psychiatr Neurosurg. 2020;56(1):44. doi: 10.1186/s41983-020-00177-0. Epub 2020 May 1.
2
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.
Ther Clin Risk Manag. 2020 Jul 22;16:651-662. doi: 10.2147/TCRM.S257714. eCollection 2020.
3
Current perspective on pandemic of COVID-19 in the United States.
J Family Med Prim Care. 2020 Apr 30;9(4):1784-1791. doi: 10.4103/jfmpc.jfmpc_424_20. eCollection 2020 Apr.
4
Consensus Statement On Immune Modulation in Multiple Sclerosis and Related Disorders During the COVID-19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology.
Ann Indian Acad Neurol. 2020 Apr;23(Suppl 1):S5-S14. doi: 10.4103/0972-2327.282442. Epub 2020 Apr 13.
5
The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China.
Front Neurol. 2021 May 28;12:682729. doi: 10.3389/fneur.2021.682729. eCollection 2021.
6
Preventive and treatment strategies of COVID-19: From community to clinical trials.
J Family Med Prim Care. 2020 May 31;9(5):2149-2157. doi: 10.4103/jfmpc.jfmpc_728_20. eCollection 2020 May.
7
A Review of Acute Myocardial Injury in Coronavirus Disease 2019.
Cureus. 2020 Jun 3;12(6):e8426. doi: 10.7759/cureus.8426.
8
Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.
Mult Scler. 2013 Jun;19(7):835-43. doi: 10.1177/1352458512471880. Epub 2013 Jan 14.
9
Closure of Universities Due to Coronavirus Disease 2019 (COVID-19): Impact on Education and Mental Health of Students and Academic Staff.
Cureus. 2020 Apr 4;12(4):e7541. doi: 10.7759/cureus.7541.
10
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002.
引用本文的文献
1
Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod.
Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):171. doi: 10.1186/s41983-021-00428-8. Epub 2021 Dec 14.
2
Complications of COVID-19 Pneumonia and Multiple Sclerosis Exacerbation.
Cureus. 2021 Aug 27;13(8):e17506. doi: 10.7759/cureus.17506. eCollection 2021 Aug.
3
Neuropsychiatric Disorders and COVID-19: What We Know So Far.
Pharmaceuticals (Basel). 2021 Sep 17;14(9):933. doi: 10.3390/ph14090933.
4
Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.
Mol Neurobiol. 2021 Sep;58(9):4694-4715. doi: 10.1007/s12035-021-02450-6. Epub 2021 Jun 24.
5
Risk and outcomes of COVID-19 in patients with multiple sclerosis.
Eur J Neurol. 2021 Nov;28(11):3712-3721. doi: 10.1111/ene.14990. Epub 2021 Jul 18.
6
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
J Neuroimmunol. 2021 Aug 15;357:577627. doi: 10.1016/j.jneuroim.2021.577627. Epub 2021 Jun 7.
7
The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China.
Front Neurol. 2021 May 28;12:682729. doi: 10.3389/fneur.2021.682729. eCollection 2021.
8
Impact of the COVID-19 pandemic on environmental awareness, sustainable consumption and social responsibility: Evidence from generations in Brazil and Portugal.
J Clean Prod. 2021 Mar 1;286:124947. doi: 10.1016/j.jclepro.2020.124947. Epub 2020 Nov 5.
9
Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients.
J Med Virol. 2021 Mar;93(3):1314-1319. doi: 10.1002/jmv.26593. Epub 2020 Oct 30.
10
COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?
J Neurol. 2021 Feb;268(2):409-419. doi: 10.1007/s00415-020-10070-8. Epub 2020 Jul 21.
本文引用的文献
1
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
2
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
3
Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action.
Cells. 2019 Jan 7;8(1):24. doi: 10.3390/cells8010024.
4
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis.
Exp Dermatol. 2018 Jun;27(6):611-624. doi: 10.1111/exd.13548. Epub 2018 Apr 25.
5
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Int J Mol Sci. 2015 Jul 20;16(7):16414-39. doi: 10.3390/ijms160716414.
6
Teriflunomide and its mechanism of action in multiple sclerosis.
Drugs. 2014 Apr;74(6):659-74. doi: 10.1007/s40265-014-0212-x.
7
The mechanism of action of interferon-β in relapsing multiple sclerosis.
CNS Drugs. 2011 Jun 1;25(6):491-502. doi: 10.2165/11591110-000000000-00000.
8
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101. doi: 10.1097/WNF.0b013e3181cbf825.
9
Natalizumab: A new treatment for relapsing remitting multiple sclerosis.
Ther Clin Risk Manag. 2007 Jun;3(2):259-68. doi: 10.2147/tcrm.2007.3.2.259.
10
Mechanism of action of rituximab.
Anticancer Drugs. 2002 Nov;13 Suppl 2:S3-10. doi: 10.1097/00001813-200211002-00002.
Zotero 插件